Advanced search
Add to list

Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
Chen, Robert W, Stephen Maxted Ansel, Pier Luigi Zinzani, et al. “Phase 1b/3 Study of Avelumab-based Combination Regimens in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).” Journal of Clinical Oncology. Vol. 35. 2017. Print.
APA
Chen, R. W., Ansel, S. M., Zinzani, P. L., Vacirca, J. L., Lopez-Guillermo, A., Hutchings, M., Jurczak, W., et al. (2017). Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). JOURNAL OF CLINICAL ONCOLOGY (Vol. 35). Presented at the Annual meeting of the American Society of Clinical Oncology (ASCO).
Chicago author-date
Chen, Robert W, Stephen Maxted Ansel, Pier Luigi Zinzani, Jeffrey L Vacirca, Armando Lopez-Guillermo, Martin Hutchings, Wojciech Jurczak, et al. 2017. “Phase 1b/3 Study of Avelumab-based Combination Regimens in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).” In Journal of Clinical Oncology. Vol. 35.
Chicago author-date (all authors)
Chen, Robert W, Stephen Maxted Ansel, Pier Luigi Zinzani, Jeffrey L Vacirca, Armando Lopez-Guillermo, Martin Hutchings, Wojciech Jurczak, Georg Hess, Steven Le Gouill, Fritz Offner, Armando Santoro, Gilles A Salles, Darla Stypinski, Douglas Laird, Dmitri Pavlov, Giovanna Andreola, Kolette D Fly, Adrian Woolfson, and Graham P Collins. 2017. “Phase 1b/3 Study of Avelumab-based Combination Regimens in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).” In Journal of Clinical Oncology. Vol. 35.
Vancouver
1.
Chen RW, Ansel SM, Zinzani PL, Vacirca JL, Lopez-Guillermo A, Hutchings M, et al. Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). JOURNAL OF CLINICAL ONCOLOGY. 2017.
IEEE
[1]
R. W. Chen et al., “Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL),” in JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL, USA, 2017, vol. 35, no. suppl. 15.
@inproceedings{8549668,
  articleno    = {abstract TPS7575},
  author       = {Chen, Robert W and Ansel, Stephen Maxted and Zinzani, Pier Luigi and Vacirca, Jeffrey L and Lopez-Guillermo, Armando and Hutchings, Martin and Jurczak, Wojciech and Hess, Georg and Le Gouill, Steven and Offner, Fritz and Santoro, Armando and Salles, Gilles A and Stypinski, Darla and Laird, Douglas and Pavlov, Dmitri and Andreola, Giovanna and Fly, Kolette D and Woolfson, Adrian and Collins, Graham P},
  booktitle    = {JOURNAL OF CLINICAL ONCOLOGY},
  issn         = {0732-183X},
  language     = {eng},
  location     = {Chicago, IL, USA},
  number       = {suppl. 15},
  title        = {Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)},
  url          = {http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.TPS7575},
  volume       = {35},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: